RE:RE:RE:RE:These guys are pretty smartpalinc2000 wrote: Sorry I still dont understand why prepaying Serono makes sense
The 23 million in debentures is interest bearing at over 1.3 million a year .
Not saying it does not make sense but questioning how you get to that conclusion without providing the yearly numbers and total costs under the 2 alternatives
The royalty part of the agreement is undisclosed so presumably you cant make that exact calculation you are looking for.
Small sidepoint. The original Serono deal was just for the HIV indication its being used for now, it didnt cover any new/future indications for the drug? Or did it? This has nothing to do with the recent non-HIV indication thats being investigated? That's still very early. Just looking to dismiss that idea. This is just about the near-term bottom line.
So following this Theratech will have ~$60million in the bank? That still seems like a limited war chest to acquire a new, already marketed drug? They'll need more for acquisitions?